Hepatitis C News and Research

Latest Hepatitis C News and Research

Skin docs prescribe costlier drugs after free samples

In other news, panels recommend a costly hepatitis C drug for the sickest patients, and cancer doctors will compare the value of costly cancer drugs.

18 Apr 2014

Deaths from viral Hepatitis B and C exceed deaths caused by HIV/AIDS

Deaths from viral Hepatitis B and C have surpassed HIV/AIDS in many countries, including Australia and in Western Europe, according to an analysis of the 2010 Global Burden of Disease study.

18 Apr 2014

First Edition: April 17, 2014

Today's headlines include reports about emerging political strategies related to the health law and the upcoming congressional elections.

17 Apr 2014

UnitedHealth Group reports strong revenue growth in Q1 2014

UnitedHealth Group today reported first quarter results, highlighted by Optum's strong growth in revenues, operating earnings and revenue backlog and UnitedHealthcare's continued strong, diversified performance despite the negative impacts of newly effective ACA taxes and regulatory provisions and sequestration cuts to Medicare.

17 Apr 2014

Entries now open for 2014 Quality in Care Hepatitis C programme

The first Quality in Care (QiC) Hepatitis C programme is now open for entry to teams and individuals working within the field of hepatitis C.

17 Apr 2014

Viewpoints: Obamacare dilemma -- some people dislike the law but embrace its provisions; are health costs falling?

Polls have consistently shown that even though the public opposes Obamacare, people like some of its most significant provisions. That's particularly true of the requirement that insurers ignore preexisting conditions when signing up customers for coverage.

16 Apr 2014

Researchers identify mechanism that explains reason for persistence of hepatitis C virus

Researchers at the University of California, San Diego School of Medicine have identified a mechanism that explains why people with the hepatitis C virus get liver disease and why the virus is able to persist in the body for so long.

16 Apr 2014

Optimal use of combination therapy achieves best treatment outcomes in patients with CHB

Three new studies presented today at the International Liver CongressTM 2014 have helped clarify the optimal use of combination therapy with peginterferon and nucleoside analogues (NUCs) to achieve the best treatment outcomes in patients with chronic hepatitis B (CHB).

16 Apr 2014

U.S. health care spending, usage rise

Americans' spending on medicines in 2013 rose 3.2 percent to nearly $330 billion, fueling speculation that a dip in overall health care spending may be over.

16 Apr 2014

Johnson & Johnson's sales increase 3.5% to $18.1 billion in first quarter 2014

Johnson & Johnson today announced sales of $18.1 billion for the first quarter of 2014, an increase of 3.5% as compared to the first quarter of 2013. Operational results increased 5.3% and the negative impact of currency was 1.8%. Domestic sales increased 2.2%. International sales increased 4.5%, reflecting operational growth of 7.9% and a negative currency impact of 3.4%.

15 Apr 2014

First Edition: April 15, 2014

Today's headlines include reports about the Congressional Budget Office's latest estimate of the costs for expanding health insurance.

15 Apr 2014

New data focuses on different approaches to improve diagnosis and treatment of HCC

Epidemiological, genetic and clinical data presented today at the International Liver CongressTM 2014 are collectively focussed on different approaches designed to improve the diagnosis, staging and treatment of hepatocellular carcinoma (HCC).

15 Apr 2014

Researchers identify new Chinese herbal medicine that inhibits hepatitis C virus activity

Data from a late-breaking abstract presented at the International Liver CongressTM 2014 identifies a new compound, SBEL1, that has the ability to inhibit hepatitis C virus (HCV) activity in cells at several points in the virus' lifecycle.

15 Apr 2014

New drug combination proves effective in treating patients with HCV genotype 1

Treatment options for the 170 million people worldwide with chronic Hepatitis C Virus (HCV) are evolving rapidly, although the available regimens often come with significant side effects. Two multi-center clinical trials led by Beth Israel Deaconess Medical Center show promise for a new option that could help lead to both an increase in patients cured with a much more simple and tolerable all oral therapy.

15 Apr 2014

High cost of potent hepatitis drug presents challenges across the U.S.

Sovaldi, the hepatitis C treatment drug, is considered a breakthrough for patients with the disease. However, since, it won federal approval in December, lawmakers, insurers and patient advocates have begun an all-out revolt over it's high price point of $1,000 a daily pill or $84,000 over 12 weeks of treatment.

15 Apr 2014

New data shows that gut microbiota has potential role in development of ALD

Exciting new data presented today at the International Liver Congress- 2014 shows that the gut microbiota has a potential role in the development of alcoholic liver disease (ALD).

15 Apr 2014

Oral therapy cures hepatitis C infection in more than 90% of patients with liver cirrhosis

Twelve weeks of an investigational oral therapy cured hepatitis C infection in more than 90 percent of patients with liver cirrhosis and was well tolerated by these patients, according to an international study that included researchers from UT Medicine San Antonio and the Texas Liver Institute.

15 Apr 2014

New paper calls for increase in geographically targeted prevention, treatment for HIV-infected people

In U.S. cities, it's not just what you do, but also your address that can determine whether you will get HIV and whether you will survive. A new paper in the American Journal of Public Health illustrates the effects of that geographic disparity - which tracks closely with race and poverty - and calls for an increase in geographically targeted prevention and treatment efforts.

11 Apr 2014

New research provides new hope for liver transplant patients with recurring hepatitis C

New research announced at the International Liver CongressTM 2014 today provides new hope for the notoriously difficult-to-treat population of liver transplant patients with recurring hepatitis C (HCV).

11 Apr 2014

EU-funded project aims to find solution to combat hepatitis C epidemic in Egypt

New ways to differentiate between chronic and self-clearing infections may help towards effective patient management and reduce drug costs. But there are major challenges in implementation.

11 Apr 2014

Hepatitis C News and Research

Latest Hepatitis C News and Research

Skin docs prescribe costlier drugs after free samples

Deaths from viral Hepatitis B and C exceed deaths caused by HIV/AIDS

First Edition: April 17, 2014

UnitedHealth Group reports strong revenue growth in Q1 2014

Entries now open for 2014 Quality in Care Hepatitis C programme

Viewpoints: Obamacare dilemma -- some people dislike the law but embrace its provisions; are health costs falling?

Researchers identify mechanism that explains reason for persistence of hepatitis C virus

Optimal use of combination therapy achieves best treatment outcomes in patients with CHB

U.S. health care spending, usage rise

Johnson & Johnson's sales increase 3.5% to $18.1 billion in first quarter 2014

First Edition: April 15, 2014

New data focuses on different approaches to improve diagnosis and treatment of HCC

Researchers identify new Chinese herbal medicine that inhibits hepatitis C virus activity

New drug combination proves effective in treating patients with HCV genotype 1

High cost of potent hepatitis drug presents challenges across the U.S.

New data shows that gut microbiota has potential role in development of ALD

Oral therapy cures hepatitis C infection in more than 90% of patients with liver cirrhosis

New paper calls for increase in geographically targeted prevention, treatment for HIV-infected people

New research provides new hope for liver transplant patients with recurring hepatitis C

EU-funded project aims to find solution to combat hepatitis C epidemic in Egypt

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Hepatitis C News and Research

Latest Hepatitis C News and Research

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Newsletters you may be interested in